FGen GmbH

FGen has commercialized the nanoliter-reactor (NLR) screening platform that enables the fast analysis of cell libraries at rates of up to 106 clones per day, thus surpassing multi-well plate relying systems by orders of magnitude. The technique is based on the encapsulation of individual clones in hydrogel-microcarriers followed by phenotypic analysis for the benchmarking and selection of candidates with desired properties. Screening in NLRs is performed under process mimicking conditions, thus increasing the probability of a successful up-scaling, and is compatible with various cell types, such as bacteria, yeast, fungi, and mammalian cells.